CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Files An 8-K Other Events
Item 8.01.Other Events.
On December 14, 2016, CytomX Therapeutics, Inc. issued a press
release announcing that the U.S. Food and Drug Administration
(FDA) has cleared the companys Investigational New Drug (IND)
application for its lead program, CX-072, a wholly-owned
PD-L1-targeting Probody therapeutic for the treatment of cancer.
The full text of the press release is furnished as Exhibit 99.1
hereto.
|
Item 9.01 |
Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto
About CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX)
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program. CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) Recent Trading Information
CYTOMX THERAPEUTICS, INC. (NASDAQ:CTMX) closed its last trading session down -0.05 at 11.48 with 126,685 shares trading hands.